Get insights into Capricor Therapeutics' Q1 2025 earnings call, featuring updates on deramiocel's regulatory progress, commercial plans, and ...

The Baloch Liberation Army claimed responsibility for seven attacks across Balochistan under 'Operation Herof 2.0,' targeting security posts, vehicles, and intelligence agents. The group vowed to ...

Q1 2025 Management View Jacqui Shea, President and CEO, highlighted that Inovio remains on track to submit its BLA for ...

Inovio Pharmaceuticals, Inc. ( NASDAQ: INO) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical Officer Steve Egge - ...

On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respirato ...

The National Institute of Allergy and Infectious Diseases (NIAID) plans to initiate phase 1 clinical trial of Capricor's ...

BLA's freedom struggle actions are part of coordinated attacks under Operation Herof 2.0 military exercise during which a total of 78 missions were carried out at 58 locations.

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights ...

The BLA has claimed responsibility for a total of 71 "coordinated attacks" at more than 51 locations across Pakistan's Balochistan province as part of its 'Operation Herof' over the last few weeks.

The FDA will issue a decision on the BLA for RGX-121 by November, which if positive, could make it the first gene therapy for Hunter syndrome.

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...